Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer02:18

Cancer

53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

6.4K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Applications of Reflectance Confocal Microscopy in Paediatric Dermatology: A Systematic Review.

Experimental dermatology·2026
Same author

Human Genome Promise-Are We There Yet?

JAMA dermatology·2026
Same author

Geographic variation in the impact of novel melanoma therapies on mortality.

Journal of the American Academy of Dermatology·2026
Same author

Differential stability of NRAS and BRAF oncoproteins in melanoma.

The Journal of investigative dermatology·2026
Same author

Germline inactivation of tumor suppressor BAP1 is associated with white spotting.

The Journal of clinical investigation·2026
Same author

Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: Jan 10, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.5K

KIT-Mutant Melanoma: Understanding the Pathway to Personalized Therapy.

Aditi Kaveti1, Ryan J Sullivan2, Hensin Tsao3

  • 1Carle Illinois College of Medicine, Champaign, IL 61801, USA.

Cancers
|November 27, 2025
PubMed
Summary

Optimal treatment strategies for KIT-mutant melanoma remain unclear. This review details KIT mutations, their clinical patterns, and therapeutic responses to targeted therapies and immunotherapies, highlighting research gaps.

Keywords:
KITexonimmunotherapyinhibitormelanomamutationtargeted therapy

More Related Videos

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.1K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.4K

Related Experiment Videos

Last Updated: Jan 10, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.5K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.1K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.4K

Area of Science:

  • Oncology
  • Dermatology
  • Genetics

Background:

  • Melanoma exhibits significant genetic heterogeneity, impacting treatment efficacy.
  • KIT mutations define a specific subtype of melanoma with less defined therapeutic strategies.

Purpose of the Study:

  • To review the associations between KIT mutations and melanoma subtypes.
  • To analyze the efficacy of c-KIT inhibitors and immune checkpoint inhibitors.
  • To identify gaps in understanding resistance and CNS progression in KIT-driven melanoma.

Main Methods:

  • Literature review of studies on KIT mutations in melanoma.
  • Analysis of clinical trials and case reports involving c-KIT inhibitors and immunotherapies.
  • Examination of resistance mechanisms and the immunogenic landscape.

Main Results:

  • KIT mutations are enriched in acral, mucosal, and sun-damaged melanomas.
  • Mutation subtype influences sensitivity to targeted therapies.
  • Combination strategies show potential for enhanced therapeutic outcomes.

Conclusions:

  • Understanding KIT function and therapeutic interactions is crucial for personalized melanoma treatment.
  • Further research is needed to address resistance, CNS progression, and the immune microenvironment in KIT-mutant melanoma.